Patents Examined by Maher M. Haddad
  • Anti-OX40 antibodies and their uses
    Patent number: 10604584
    Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: March 31, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Fiona A. Harding
  • Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
    Patent number: 10597455
    Abstract: Methods and compositions comprising integrin ?8 antibodies are provided.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: March 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson
  • Suppression of SPLA2-integrin binding for treating an inflammatory condition or suppressing cell proliferation
    Patent number: 10591471
    Abstract: The present invention relates to the discovery that a secretory phospholipase A2 (sPLA2-IIA) plays an active role in mediating cellular signaling leading to an inflammatory response or cell proliferation by way of its specific binding with integrin ? at site 2 of integrin ?. More specifically, the invention provides a method for identifying inhibitors of inflammatory or proliferative signaling by screening for compounds that interrupt the specific binding of sPLA2 and integrin ? at site 2. The invention also provides the novel use of a substance that suppresses the specific binding between sPLA2 and site 2 of integrin? for the purpose of treating or preventing a condition involving an undesired inflammatory response or cell proliferation.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Yoshikazu Takada, Yoko Takada, Masaaki Fujita
  • Anti-MCAM antibodies and associated methods of use
    Patent number: 10584177
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 10, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Antibodies binding CD40 and uses thereof
    Patent number: 10570210
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 25, 2020
    Assignee: Beijing Mabworks Biotech Co.Ltd
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
    Patent number: 10562974
    Abstract: A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 18, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Sandro De Falco
  • Mesenchymal stem cell differentiation
    Patent number: 10555990
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 11, 2020
    Assignees: NOVARTIS AG, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz
  • Anti-ADAM28 antibody for treating cancer
    Patent number: 10556967
    Abstract: The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: February 11, 2020
    Assignees: GENEFRONTIER CORPORATION, KEIO UNIVERSITY
    Inventors: Akira Miyakoshi, Rena Matsumoto, Shizue Katoh, Yuki Hayami, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
  • Anti-OX40 antibodies and their uses
    Patent number: 10556962
    Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: February 11, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Fiona A. Harding
  • Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)
    Patent number: 10550186
    Abstract: Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting ICAM4. While MDSCs in mice have been extensively characterized, their human counterparts are not well defined, and cell markers present in mice are not always usable in humans. MDSCs have been described as a heterogenous population of myeloid derived cells with immune suppressive capacity (5, 9, 40, 41). Recent renewed interest in the role of MDSC accumulation in human tumors has resulted in the increased need to define these cells better in order to target them for therapeutic intervention.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: February 4, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Zaheed Husain
  • Anti-TIM-3 antibody
    Patent number: 10550181
    Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 4, 2020
    Assignees: KYOWA KIRIN CO., LTD, Kyushu University, National University Corporation
    Inventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
  • Anti-tenascin C antibodies and uses thereof
    Patent number: 10533047
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: January 14, 2020
    Assignee: NASCIENT LIMITED
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • Pentapeptide associated with integrin receptor alpha vbeta3
    Patent number: 10526370
    Abstract: A pentapeptide associated with integrin receptor ?v?3, which has a sequence of arginine-tryptophan-arginine-asparagine-methionine. The pentapeptide targets tumor cells highly expressing ?v?3, but not tumor cells lowly expressing ?v?3 and normal cells. Accordingly, the pentapeptide is useful in the diagnosis and treatment of cancers.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: January 7, 2020
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Yueqing Gu, Congying Zhang, Menglu Zhao, Qian Wang, Caiping Tian, Yuxi Liu
  • Disintegrin variants and pharmaceutical uses thereof
    Patent number: 10508137
    Abstract: Disintegrin variants that bind specifically to one or more of ?5?1 and ?v integrins, such as ?v?1, ?v?3, ?v?5, ?v?6 and ?v?8, but with reduced binding activity to ?IIb?3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an ?v integrin or an ?5?1 integrin.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 17, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERISTY
    Inventor: Woei-Jer Chuang
  • Engineered antibody for inhibition of fibrosis
    Patent number: 10501533
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 10, 2019
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • JAML specific binding agents, antibodies, and uses related thereto
    Patent number: 10465005
    Abstract: Certain embodiments of the disclosure relate to targeted binding agents that specifically bind to JAM-like protein and therein inhibit epithelial damage. Although it is not intended that embodiments of the disclosure be limited by any particular mechanism, it is believed that a possible mechanism by which this can be achieved may include, but are not limited to, either inhibition of binding of JAML to the CAR, inhibition of JAML induced CAR signaling, or increased clearance of JAML from the body of a subject, therein reducing the effective concentration of soluble JAML. In certain embodiment, the specific binding agent is a fully human antibody or chimera that specifically binds to human JAML, such as the JAML D1, and prevents JAML binding to CAR. Certain embodiments of the disclosure contemplate antibodies comprising human IgG type, e.g., IgG1, IgG2, IgG3, and IgG4.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 5, 2019
    Assignee: Emory Patent Group
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Compounds binding to JMJD6 with antifibrotic activity
    Patent number: 10457746
    Abstract: The present invention relates to the interaction between JMJD6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and JMJD6 protein, in particular the invention relates to a new monoclonal antibody that recognizes JMJD6 and is able to block this interaction.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 29, 2019
    Assignee: FONDAZIONE IRCCS “INSTITUTO NAZIONALE DEI TUMORI”
    Inventors: Mario Paolo Colombo, Silvia Miotti, Elda Tagliabue, Sabina Sangaletti
  • Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
    Patent number: 10450371
    Abstract: The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: October 22, 2019
    Assignees: Indiana University Research and Technology Corporation, United States Government as represented by the Department of Veterans Affairs
    Inventors: Matthias Clauss, Irina Petrache, Robert Voswinckel
  • Antibodies binding OX40 and uses thereof
    Patent number: 10442866
    Abstract: An isolated monoclonal antibody that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: October 15, 2019
    Assignee: Beijing Mabworks Biotech Co. Ltd
    Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio